Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × Interleukin 1 Receptor Antagonist Protein × Clear all

NCT04432506 2025-01-28

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Completed

22 enrolled 15 charts

LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms